When patients are started on darbepoetin alfa (Aranesp) they need ...

[EAugust]

When patients are started on darbepoetin alfa (Aranesp) they need monitoring of their blood counts to determine a dosage adjustment in:
 
  1. 6 weeks if they are a cancer patient
  2. 1 week if they have chronic renal failure
  3. 2 weeks if they are taking it for allogenic transfusion
  4. Each week throughout therapy

Question 2

The FDA issued a safety announcement regarding the use of erythropoiesis-stimulating agents (ESAs) in 2010 with the recommendation that:
 
  1. ESAs no longer be prescribed to patients with chronic renal failure
  2. The risk of tumor development be explained to cancer patients on ESA therapy
  3. Patients should no longer receive ESA therapy to prepare for allogenic transfusions
  4. ESAs be prescribed only to patients younger than age 60 years
 
  ___

[joshraies]

Answer to Question 1

1

Answer to Question 2

2

[EAugust]

Thank you!

[joshraies]

Always glad to help...